Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties

Outcomes summary

Comprehensive review of 25 years of epitalon research analyzing in vitro, in vivo, and in silico studies. Reports significant geroprotective and neuroendocrine effects with antioxidant, neuro-protective, and antimutagenic properties. Discusses mechanisms including telomeras activation, melatonin synthesis regulation, IL-2 modulation, and enzyme activities. Covers administration routes (subcutaneous, oral, intranasal, parabulbar), animal study dosing (1 µg/mouse, 5 times/week), and notes that human safety data is missing. States short peptides like epitalon are typically unstable and degrade rapidly in vivo.

Limitations

Review article synthesizing preclinical data; no new primary data presented. Evidence primarily from animal/in vitro studies; human clinical data limited and insufficient for establishing safety/efficacy. Specific pharmacokinetic data not reported. Authors explicitly note safety data is missing for toxicity, genotoxicity, carcinogenic potential, and drug interactions.

Notes

Primary source: PMID 40141333, International Journal of Molecular Sciences 2025;26(6):2691. DOI: 10.3390/ijms26062691. Open access review analyzing 25 years of epitalon research.